Alcoholic Liver Disease Clinical Trial
Official title:
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease - A Randomized Control Trial
Patient found to be malnourished after the nutritional evaluation would be randomized in the two groups of the study. The control group would receive standard nutritional counseling from a trained dietician where as those in the intervention group would be given 120 gm of a polymeric nutritional supplement providing around 500 Kcal per day over and above the standard nutritional counseling from a trained dietician. Both the groups would receive standard medical treatment. The polymeric nutrient supplement would be taken by the patients in this arm for a period of 6 months.
Patients with ALD (Alcoholic Liver Disease) would undergo a detailed clinical evaluation.
Information would be collected regarding the onset and duration of symptoms, etiology, and
severity of disease, other baseline clinical features, demographic characteristics, routine
biochemical and hematological investigations, upper GI endoscopic findings and radiological
investigations, patients would also be screened for the assessment of nutritional status.
Patient found to be malnourished after the nutritional evaluation would be randomized in the
two groups of the study. The control group would receive standard nutritional counseling
from a trained dietician where as those in the intervention group would be given 120 gm of a
polymeric nutritional supplement providing around 500 Kcal per day over and above the
standard nutritional counseling from a trained dietician. Both the groups would receive
standard medical treatment. The polymeric nutrient supplement would be taken by the patients
in this arm for a period of 6 months. A record would be kept for the medications taken by
the patients.
All the patients would be followed up at 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3
months, 6 months, and 1 year after inclusion. Clinical, nutritional and biological data were
collected at each visit. All these patients would receive standard treatment of cirrhosis
consisting of withdrawal from alcohol along with symptomatic treatment including B vitamins,
diuretics, salt restriction, lactulose, beta blockers, and antibiotics after bacteriological
samples if needed. All patients would receive endoscopic surveillance for portal
hypertension. An adequate prophylaxis by ligation or beta blockers would be performed as
needed. The patients with a past history of spontaneous bacterial peritonitis will receive
antibiotic prophylaxis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00708617 -
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
|
N/A | |
Completed |
NCT00990639 -
Effect of Candesartan in Alcoholic Liver Fibrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106518 -
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
|
||
Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Completed |
NCT01501162 -
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
|
Phase 4 | |
Recruiting |
NCT05895890 -
French National MICMAF Cohort
|
||
Completed |
NCT04557774 -
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
|
||
Recruiting |
NCT03267069 -
Evaluating Alcohol Use in Alcoholic Liver Disease
|
||
Recruiting |
NCT03295812 -
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
|
N/A | |
Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
Not yet recruiting |
NCT03503708 -
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
|
N/A | |
Completed |
NCT02796469 -
Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Recruiting |
NCT03209791 -
Ethanol Induces Skeletal Muscle Autophagy
|
||
Recruiting |
NCT04736966 -
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
|
Phase 1 | |
Recruiting |
NCT04400604 -
Study of Alcohol-related Liver Disease in Europe
|
||
Completed |
NCT03402256 -
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
|
N/A | |
Completed |
NCT01711125 -
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A | |
Not yet recruiting |
NCT06307964 -
Intra-Hepatic Microbiota in Alcoholic Hepatitis
|